BridgeBio Pharma, Inc. terminated Equity Distribution Agreement, dated May 4, 2023 with Goldman Sachs & Co. LLC and Leerink Partners LLC (formerly known as SVB Securities LLC) (effective 2026-05-07).
“On May 7, 2026, in connection with entering into the Agreement, the Company agreed with Goldman Sachs and Leerink Partners (formerly known as SVB Securities LLC), to terminate that certain Equity Distribution Agreement, dated May 4, 2023, by and among the Company, Goldman Sachs and Leerink Partners, effective as of May 7, 2026.”
Material Agreements
BridgeBio Pharma, Inc. entered into Equity Distribution Agreement with Goldman Sachs & Co. LLC and Leerink Partners LLC valued at $500,000,000 (effective 2026-05-07).
“On May 7, 2026, the Company entered into an Equity Distribution Agreement (the “Agreement”) with Goldman Sachs & Co. LLC (“Goldman Sachs”) and Leerink Partners LLC (“Leerink Partners”, and together with Goldman Sachs, the “Sales Agents”) with respect to an “at-the-market” offering program under which the Company may issue and sell, from time to time at its sole discretion and pursuant to a prospectus supplement, shares of its common stock, par value $0.001 per share (“Common Stock”), having an aggregate offering price of up to $500,000,000 (the “Placement Shares”), through the Sales Agents.”
Earnings Releases
BridgeBio Pharma, Inc. reported the first quarter ended March 31, 2026 results: revenue $194.5 million.
“except as expressly set forth by specific reference in such a filing. --- EX-99.1 (EX-99.1) --- BridgeBio Reports First Quarter 2026 Financial Results and Corporate Updates - $194.5 million in total first quarter revenues, comprised of $180.6 million of U.S. Attruby® net product revenue, with strong prescribing growth and patient persistence driving continued”
Equity Issuances
BridgeBio Pharma, Inc. issued convertible note to qualified institutional buyers for $632.5 million aggregate principal amount.
“BridgeBio Pharma, Inc. (“BridgeBio”) issued an aggregate of $632.5 million aggregate principal amount of its 0.75% Convertible Senior Notes due 2033 (the “Notes”), pursuant to an Indenture dated January 21, 2026 (the “Indenture”), between BridgeBio and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”), in a private offering to qualified institutional buyers”
Debt Financings
BridgeBio Pharma, Inc. incurred convertible notes of $632.5 million aggregate principal amount with qualified institutional buyers at 0.75% per year maturing February 1, 2033.
“BridgeBio Pharma, Inc. (“BridgeBio”) issued an aggregate of $632.5 million aggregate principal amount of its 0.75% Convertible Senior Notes due 2033 (the “Notes”), pursuant to an Indenture dated January 21, 2026”
Material Agreements
BridgeBio Pharma, Inc. entered into 0.75% Convertible Senior Notes due 2033 Indenture with U.S. Bank Trust Company, National Association valued at $632,500,000 aggregate principal amount (effective 2026-01-21).
“On January 21, 2026, BridgeBio Pharma, Inc. (“BridgeBio”) issued an aggregate of $632.5 million aggregate principal amount of its 0.75% Convertible Senior Notes due 2033 (the “Notes”), pursuant to an Indenture dated January 21, 2026 (the “Indenture”), between BridgeBio and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”), in a private offering to qualified institutional buyers (the “Note Offering”) pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”).”
Governance Changes
BridgeBio Pharma, Inc.: Amendment to Certificate of Incorporation to include an officer exculpation provision limiting liability of certain officers as permitted by Delaware law (effective 2025-06-23).
“an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended and/or restated from time to time (the “Certificate of Incorporation”) to limit the liability of certain officers of the Company as permitted under current Delaware law (the “Officer Exculpation Amendment”).”
Brian C. Stephenson departed as Chief Financial Officer at BridgeBio Pharma, Inc..
“The employment of Brian C. Stephenson, the Chief Financial Officer of BridgeBio Pharma, Inc. (the “Company”), ended on March 17, 2025 (the “Effective Date”).”
Debt Financings
BridgeBio Pharma, Inc. incurred convertible notes of $575.0 million aggregate principal amount of 1.75% Convertible Senior Notes due 2031 with Qualified Institutional Buyers at 1.75% per year maturing March 1, 2031.
“On February 28, 2025, BridgeBio Pharma, Inc. (“BridgeBio”) issued an aggregate of $575.0 million aggregate principal amount of its 1.75% Convertible Senior Notes due 2031 (the “Notes”), pursuant to an Indenture dated February 28, 2025 (the “Indenture”), between BridgeBio and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”), in a private offering to qualified institutional buyers (the “Note Offering”) pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”).”
Neil Kumar changed role as President at BridgeBio Pharma, Inc..
“Neil Kumar, Ph.D. stepped down as President”
Thomas Trimarchi was appointed as President and Chief Operating Officer at BridgeBio Pharma, Inc..
“Thomas Trimarchi was appointed as the Company’s President and Chief Operating Officer”
Earnings Releases
BridgeBio Pharma, Inc. reported financial results for first quarter ended March 31, 2024.
“BridgeBio Pharma, Inc. reported recent business updates and its financial results for the first quarter ended March 31, 2024.”
Material Agreements
BridgeBio Pharma, Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC, Cantor Fitzgerald & Co. and Mizuho Securities USA LLC, as representatives of the several underwriters valued at approximately $250.0 million (effective 2024-03-05).
“On March 5, 2024, BridgeBio Pharma, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Cantor Fitzgerald & Co. and Mizuho Securities USA LLC, as representatives of the several underwriters listed on Schedule I thereto (collectively, the “Underwriters”), relating to an underwritten public offering (the “Offering”) of 8,620,690 shares of the Company's common stock, $0.001 par value per share (the “Common Stock”), at a price to the public of $29.00 per share.”
Material Agreements
BridgeBio Pharma, Inc. entered into Agreement with Bayer Consumer Care AG valued at up to $310 million in upfront, regulatory, and sales milestone payments (effective 2024-03-01).
“On March 1, 2024, certain subsidiaries of BridgeBio Pharma, Inc. (the “Company”), including Eidos Therapeutics, Inc. (“Eidos”), BridgeBio International GmbH and BridgeBio Europe B.V., entered into an exclusive license agreement (the “Agreement”) with Bayer Consumer Care AG, a wholly-owned subsidiary of Bayer AG (“Bayer”), to develop and commercialize acoramidis as a treatment for transthyretin amyloidosis in the European Union and all member states of the European Patent Organization (the “Licensed Territory”).”
Earnings Releases
BridgeBio Pharma, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.
“BridgeBio Pharma, Inc. reported recent business updates and its financial results for the fourth quarter and full year ended December 31, 2023.”
Debt Financings
BridgeBio Pharma, Inc. incurred term loan of $450,000,000 with Blue Owl Capital Corporation, as administrative agent at Term SOFR plus 6.75% maturing January 17, 2029.
“On the Closing Date, the Company entered into a Financing Agreement (the “Financing Agreement”) with certain of its subsidiaries party thereto as guarantors, the lenders party thereto (the “Lenders”) and Blue Owl Capital Corporation, as administrative agent for the Lenders (the “Administrative Agent”). Pursuant to the terms and conditions of the Financing Agreement, the Lenders have agreed to extend a senior secured credit facility to the Company in an aggregate principal amount of up to $750,000,000, comprised of (i) an initial term loan in an aggregate principal amount of $450,000,000 (the “Initial Term Loan”)”
Material Agreements
BridgeBio Pharma, Inc. entered into Financing Agreement with Blue Owl Capital Corporation, as administrative agent valued at $750,000,000 (effective 2024-01-17).
“On the Closing Date, the Company entered into a Financing Agreement (the “Financing Agreement”) with certain of its subsidiaries party thereto as guarantors, the lenders party thereto (the “Lenders”) and Blue Owl Capital Corporation, as administrative agent for the Lenders”
Material Agreements
BridgeBio Pharma, Inc. entered into Funding Agreement with LSI Financing 1 Designated Activity Company and CPPIB Credit Europe S.à r.l. valued at $500,000,000 (effective 2024-01-17).
“entered into a Funding Agreement (the “Funding Agreement”) with LSI Financing 1 Designated Activity Company and CPPIB Credit Europe S.à r.l. (together, the “Purchasers”)”
Earnings Releases
BridgeBio Pharma, Inc. reported financial results for third quarter ended September 30, 2023.
“On November 2, 2023, BridgeBio Pharma, Inc. reported recent business updates and its financial results for the third quarter ended September 30, 2023.”
Material Agreements
BridgeBio Pharma, Inc. entered into Purchase Agreement with certain accredited investors valued at approximately $250 million (effective 2023-09-25).
“On September 25, 2023, BridgeBio Pharma, Inc. (the “Company”) and certain accredited investors (each an “Investor” and collectively, the “Investors”) entered into a securities purchase agreement (the “Purchase Agreement”) pursuant to which the Company agreed to sell and issue to the Investors in a private placement (the “Private Placement”) an aggregate of 9,167,723 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a purchase price of $27.27 per share.”
Earnings Releases
BridgeBio Pharma, Inc. reported financial results for the second quarter ended June 30, 2023.
“On August 3, 2023, BridgeBio Pharma, Inc. reported recent business updates and its financial results for the second quarter ended June 30, 2023.”
Shareholder Votes
BridgeBio Pharma, Inc. shareholders approved Ratification of appointment of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-21 meeting.
“Proposal 3 - Ratification of Appointment of Independent Registered Accounting Firm. The Company’s stockholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2023. Votes For Votes Against Abstentions 148,795,806 21,960 20,383 There were zero broker non-votes regarding this proposal.”
Shareholder Votes
BridgeBio Pharma, Inc. shareholders approved Non-binding advisory vote on compensation of named executive officers at the 2023-06-21 meeting.
“Proposal 2 - Non-binding Advisory Vote on Compensation of Named Executive Officers. The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers. Votes For Votes Against Abstentions 104,001,511 29,901,611 45,622 There were 14,889,405 broker non-votes regarding this proposal.”
Shareholder Votes
BridgeBio Pharma, Inc. shareholders approved Election of four Class I director nominees to hold office until the 2026 Annual Meeting at the 2023-06-21 meeting.
“Proposal 1 - Election of Directors. The Company’s stockholders elected the four (4) director nominees below to the Company’s Board of Directors as Class I directors to hold office until the 2026 Annual Meeting of Stockholders of the Company or until their successors are duly elected and qualified. Director Nominee Votes For Votes Withheld James C. Momtazee 126,983,947 6,964,797 Frank McCormick, Ph.D. 126,128,725 7,820,019 Randal W. Scott, Ph.D. 131,253,639 2,695,105 Hannah A. Valantine, M.D. 107,393,329 26,555,415 There were 14,889,405 broker non-votes regarding this proposal.”
Material Agreements
BridgeBio Pharma, Inc. terminated Open Market Sales Agreement with Jefferies LLC and SVB Securities LLC (effective 2023-05-03).
“On May 3, 2023, Jefferies LLC (“Jefferies”) and SVB Securities LLC (formerly known as SVB Leerink LLC, “SVB Securities”), acknowledged and accepted the Company’s prior written notice to terminate the Open Market Sales Agreement SM , dated July 7, 2020, by and among the Company, Jefferies and SVB Securities, for convenience, effective as of May 3, 2023.”
Material Agreements
BridgeBio Pharma, Inc. entered into Equity Distribution Agreement with Goldman Sachs & Co. LLC and SVB Securities LLC valued at up to $450,000,000 (effective 2023-05-04).
“On May 4, 2023, the Company entered into an Equity Distribution Agreement (the “Agreement”) with Goldman Sachs & Co. LLC and SVB Securities LLC (the “Sales Agents”) with respect to an “at-the-market” offering program under which the Company may issue and sell, from time to time at its sole discretion and pursuant to a prospectus supplement, shares of its common stock, par value $0.001 per share (“Common Stock”), having an aggregate offering price of up to $450,000,000 (the “Placement Shares”), through the Sales Agents.”
Material Agreements
BridgeBio Pharma, Inc. entered into Underwriting Agreement with Goldman Sachs & Co. LLC, Evercore Group L.L.C. and Morgan Stanley & Co. LLC valued at $17.00 per share (effective 2023-03-07).
“On March 7, 2023, BridgeBio Pharma, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC, Evercore Group L.L.C. and Morgan Stanley & Co. LLC, as representatives of the several underwriters listed on Schedule I thereto (collectively, the “Underwriters”), relating to an underwritten public offering (the “Offering”) of 8,823,530 shares of the Company’s common stock, $0.001 par value per share (the “Common Stock”), at a price to the public of $17.00 per share.”
Earnings Releases
BridgeBio Pharma, Inc. reported financial results for the full year ended December 31, 2022.
“BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today reported its financial results for the fourth quarter and full year ended December 31, 2022 and provided an update on the Company's operations.”
Earnings Releases
BridgeBio Pharma, Inc. reported financial results for the fourth quarter ended December 31, 2022.
“BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today reported its financial results for the fourth quarter and full year ended December 31, 2022 and provided an update on the Company's operations.”
Frank McCormick was appointed as Director at BridgeBio Pharma, Inc..
“On February 23, 2023, the Company announced that Frank McCormick, Ph.D., F.R.S., D.Sc. (Hon) has been appointed by the Board to serve as a director of the Company and fill the vacancy created by the resignation of Dr. Scheller.”
Brenton L. Saunders resigned as Director at BridgeBio Pharma, Inc..
“On February 21, 2023, Richard H. Scheller, Ph.D. and Brenton L. Saunders each notified BridgeBio Pharma, Inc. (the “Company”), of his decision to resign as a member of the Board of Directors of the Company (the “Board”) effective as of February 21, 2023, and on or about March 6, 2023, respectively.”
Richard H. Scheller resigned as Director at BridgeBio Pharma, Inc..
“On February 21, 2023, Richard H. Scheller, Ph.D. and Brenton L. Saunders each notified BridgeBio Pharma, Inc. (the “Company”), of his decision to resign as a member of the Board of Directors of the Company (the “Board”) effective as of February 21, 2023, and on or about March 6, 2023, respectively.”
Debt Financings
BridgeBio Pharma, Inc. amended credit facility with U.S. Bank Trust Company, National Association (as administrative agent) and the Lenders.
“Pursuant to the terms and conditions of the Second Amendment, the parties thereto agreed to, among other things: (1) acknowledge that the Company’s prior prepayment made with certain cash proceeds received in connection with that certain License, Development and Commercialization Agreement, dated as of May 11, 2022, by and among Navire Pharma, Inc., the Company and Bristol-Myers Squibb Company satisfied the mandatory prepayment requirement under the Amended Loan Agreement, on the terms and conditions specified in the Amended Loan Agreement, (2) permit certain budgeted expenses to be excluded from the definition of cash proceeds subject to Borrower’s mandatory prepayment obligations, on the terms and conditions specified in the Amended Loan Agreement, (3) remove certain threshold amounts applicable to certain prepayment events and (4) terminate the Lenders’ tranche 2 commitments.”
Material Agreements
BridgeBio Pharma, Inc. amended Second Amendment to Loan and Security Agreement with U.S. Bank Trust Company, National Association (as agent) and the lenders party thereto (effective 2022-11-30).
“On November 30, 2022, BridgeBio Pharma, Inc. (“BridgeBio” or the “Company”) entered into a Second Amendment to Loan and Security Agreement (the “Second Amendment”), by and among (i) U.S. Bank Trust Company, National Association, as successor to U.S. Bank National Association, in its capacity as administrative agent (in such capacity, the “Administrative Agent”) and collateral agent (in such capacity, the “Collateral Agent”), (ii) the certain lenders party thereto (the “Lenders”), (iii) the Company, as a borrower, and (iv) certain subsidiaries of the Company, as guarantors (the “Guarantors”), pursuant to which the parties thereto agreed to amend the Loan and Security Agreement, dated as of November 17, 2021, as amended by the First Amendment to Loan and Security Agreement, dated as of May 12, 2022 (the “Existing Loan Agreement”, and amended by the Second Amendment, the “Amended Loan Agreement”), by and among the Company, Guarantors, Lenders, the Administrative Agent and the Collateral A”
Earnings Releases
BridgeBio Pharma, Inc. reported financial results for the third quarter ended September 30, 2022.
“BridgeBio Pharma, Inc. (the “Company”) reported recent business updates and its financial results for the third quarter ended September 30, 2022.”
Dr. Hannah A. Valantine was appointed as Director at BridgeBio Pharma, Inc..
“Effective as of October 23, 2021, the Board, upon the recommendation of the Nominating and Corporate Governance Committee, appointed Dr. Hannah A. Valantine to the Board.”
Douglas Dachille was appointed as Director at BridgeBio Pharma, Inc..
“the Board, upon the recommendation of the Nominating and Corporate Governance Committee, appointed Fred Hassan, Andrea Ellis and Douglas Dachille to the Board.”
Andrea Ellis was appointed as Director at BridgeBio Pharma, Inc..
“the Board, upon the recommendation of the Nominating and Corporate Governance Committee, appointed Fred Hassan, Andrea Ellis and Douglas Dachille to the Board.”
Fred Hassan was appointed as Director at BridgeBio Pharma, Inc..
“the Board, upon the recommendation of the Nominating and Corporate Governance Committee, appointed Fred Hassan, Andrea Ellis and Douglas Dachille to the Board.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.